What is IGF-1 LR3?

A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

IGF-1 LR3 in the library · · Human Trials · What are peptides?

47 registered trials · 318 indexed papers · 985 human / 380 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h. Called the "nuclear option" of growth peptides.

Mechanism (as described)

Drives muscle hyperplasia (new cells), not just hypertrophy.
Not site-specific. Once in the blood it signals everywhere, including the heart, liver, kidneys and gut.

Registered human trials (47)

Trial	Phase	Status	Year	Enrolled
Impact of Filtration on Autologous Serum Eye Drops		completed	2026	10
Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir		completed	2025	60
Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence		completed	2025	60
Efficacy of Insulin Like Growth Factor-1(IGF-1) on Bone Regeneration in Intrabony Defects : A Clinico-radiograph Study		unknown	2023	24
Health Status of Children Born After Assisted Reproductive Technologies		completed	2023	252
A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1)		completed	2023	25
Study of Parameters of Osteosarcopenia in Patients With Hip Fracture		recruiting	2020	100
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants	Phase 2	active not recruiting	2019	295
Gene Expression Changes In Young and Geriatric Skin	EARLY_Phase 1	recruiting	2019	24
Nutrition and Growth in Very Preterm Infants		completed	2019	180
NMES Effects on Substrate Metabolism and IGF-1		completed	2017	24
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma	Phase 1/Phase 2	terminated	2017	14
Effect of Maternal BMI and Type of Infants Feeding on IGF-1 in Infant		unknown	2017	40
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency	Phase 1/Phase 2	completed	2015	7
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)	Phase 2	completed	2015	76
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder	Phase 2	terminated	2014	3
Treatment of Rett Syndrome With Recombinant Human IGF-1	Phase 2	completed	2013	30
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)	Phase 2	completed	2012	19
Increlex Treatment of Children With Chronic Liver Disease and Short Stature		withdrawn	2011
Effects of Anorexia Nervosa on Peak Bone Mass	Phase 3	completed	2011	75
IGF-1 and Bone Loss in Women With Anorexia Nervosa		completed	2011	148
Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack	Phase 1/Phase 2	completed	2011	47
Effects of IGF-I in HIV Metabolic Disease	Phase 1	terminated	2011	16
Growth Hormone (GH) Deficiency & Insulin Like Growth Factor 1 (IGF-I)/ Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio		completed	2011	134
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung	Phase 2	completed	2011	100
IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients		completed	2011	15
IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations		completed	2011	8
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity	Phase 2	completed	2010	121
Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy	Phase 1/Phase 2	completed	2010	44
Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)	Phase 1	completed	2010	12
Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)	Phase 3	completed	2009	14
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).		recruiting	2008	500
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors	Phase 1/Phase 2	terminated	2008	5
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)		completed	2008	28
Effect of Increlex® on Children With Crohn Disease	Phase 2/Phase 3	terminated	2008	3
IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment		completed	2008	589
IGF-1 Therapy in Patients With Cystic Fibrosis	Phase 1	terminated	2008	15
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency	Phase 2	terminated	2007	106
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents	Phase 1/Phase 2	completed	2007	16
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1	Phase 1/Phase 2	terminated	2007	6

Peer-reviewed studies (318)

Paper	Authors	Journal	Year	Type
Elevated IGF-1 levels are associated with accelerated bone age advancement during growth hormone therapy in children: a multicenter cohort study	Ahn J et al.	Frontiers in endocrinology	2026	Observational Study
Growth parameters and IGF-1 axis biomarkers differ among omnivorous, vegetarian, and vegan children	Allner IE et al.	European journal of nutrition	2026	Observational Study
First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240	Nishizaki H et al.	European journal of endocrinology	2026	Randomized Controlled Trial
Lifestyle intervention based on aerobic exercise and Mediterranean diet modulates IGF-1 and its binding proteins in breast cancer survivors	Annibalini G et al.	Breast cancer research : BCR	2026	Randomized Controlled Trial
Early pregnancy concentrations of pregnancy-associated plasma protein-A (PAPP-A) and insulin-like growth factor-1 (IGF-1) following frozen embryo transfer: secondary analyses from a randomized controlled trial	Mørch NF et al.	Human reproduction (Oxford, England)	2026	Randomized Controlled Trial
Weight Regain Reverses Caloric Restriction-Induced Benefits on the Insulin-IGF-1 Nutrient-Sensing Pathway: Post Hoc Analysis From the CALERIE-2 Randomized Controlled Trial	Warmbrunn MV et al.	Diabetes care	2026	Randomized Controlled Trial
Lorcaserin induces abdominal fat loss with associated improvements of the circulating metabolome/lipidome and no changes in the myostatin-activin-follistatin-IGF-1 axes: A 6-month long randomized placebo-controlled clinical trial	Ramirez-Cisneros A et al.	Diabetes, obesity & metabolism	2026	Randomized Controlled Trial
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study	Gutierrez de Piñeres V et al.	Diabetes research and clinical practice	2026	Randomized Controlled Trial
Assessment of Growth Hormone and Insulin-Like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophica	El Darouti M et al.	Pediatric dermatology	2026	Observational Study
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study	Gutierrez de Piñeres V et al.	Diabetes, obesity & metabolism	2026	Randomized Controlled Trial
Association of IGF-1 Levels With Height From Childhood to Adulthood: An Observational and Mendelian Randomization Study	De La Barrera B et al.	The Journal of clinical endocrinology and metabolism	2026	Observational Study
Acute effects of neuromuscular electrical stimulation on lactate, IGF-1 and cognition in chronic spinal cord injury: A pilot randomized cross-over study	Vints WAJ et al.	The journal of spinal cord medicine	2026	Randomized Controlled Trial
Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data	Ramon-Krauel M et al.	The Journal of clinical endocrinology and metabolism	2026	Observational Study
The Effects of Lactobacillus paracasei NB23 on IGF-1, Muscle Function, and Cardiometabolic Risk Factors in Healthy Individuals: A Randomized Controlled Trial	Lin SW et al.	Probiotics and antimicrobial proteins	2026	Randomized Controlled Trial
A cross-sectional study of urinary sodium, cardiac remodeling, and the mediating role of insulin-like growth factor-1: Insights from the UK Biobank	Yan D et al.	Medicine	2025	Observational Study
Long-term clinical control in acromegaly patients with postoperative discordant nadir growth hormone during oral glucose tolerance test and insulin-like growth factor 1 levels: a retrospective observational study and literature review	Ishida T et al.	Langenbeck's archives of surgery	2025	Observational Study
Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55-70 Years): Findings from a Randomised Double-Blinded Controlled Trial	Farhat G et al.	Nutrients	2025	Randomized Controlled Trial
Impacts of resistance training combined with vibration training on the IGF-1/PI3K/AKT/FOXO3 axis and clinical outcomes in patients with sarcopenia: A protocol for a randomized controlled trial	Zhou H et al.	PloS one	2025	Clinical Study
IGF-1 as a biomarker for symptom severity in adolescents with traumatic brain injury	Mishra V et al.	Brain injury	2025	Observational Study
Gestational diabetes mellitus: the role of IGF-1 and leptin in cord blood	Krause A et al.	Journal of perinatal medicine	2025	Observational Study
Protein intake and insulin-like growth factor-1 at 12 months and associations with growth, body composition, and metabolic syndrome at 8 years	Seidal GO et al.	Journal of pediatric gastroenterology and nutrition	2025	Observational Study
Cord blood levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 correlate with perinatal brain development in fetal congenital heart disease	Nijman M et al.	Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology	2025	Observational Study
Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial	Salah H et al.	Cancer chemotherapy and pharmacology	2025	Randomized Controlled Trial
Post-Exercise Whey Protein Supplementation: Effects on IGF-1, Strength, and Body Composition in Pre-Menopausal Women, a Randomised Controlled Trial	Murray M et al.	Nutrients	2025	Randomized Controlled Trial
Effect of aerobic or resistance exercise, or both on insulin secretion, ciliary neurotrophic factor, and insulin-like growth factor-1 in dieting older adults with obesity	Colleluori G et al.	Clinical nutrition (Edinburgh, Scotland)	2025	Randomized Controlled Trial
Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis	Gu X et al.	International journal of clinical pharmacology and therapeutics	2025	Randomized Controlled Trial
Effect of pyridostigmine on growth hormone and IGF-1 levels and outcomes of controlled ovarian stimulation cycle in women with poor ovarian response	Karimi R et al.	Archives of gynecology and obstetrics	2025	Randomized Controlled Trial
Scp776, A Novel IGF-1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo-Controlled Phase 1 Studies in Healthy Adults	Pfaff SJ et al.	Clinical pharmacology in drug development	2025	Randomized Controlled Trial
Impact of lifestyle intervention on vitamin D, Adiponectin, Insulin-like growth factor 1 and Proneurotensin in overweight individuals from the Middle East	Dhaher NF et al.	Primary care diabetes	2024	Randomized Controlled Trial
Predictive value of IGF-1/IGFBP-3 ratio for thyroid nodules in type 2 diabetic mellitus	Liu B et al.	Frontiers in endocrinology	2024	Observational Study

More cited research

Recombinant human insulin-like growth factor 1 complex preserves lung development in mechanically ventilated preterm lambs (2026, human observational)
Characterization of Primary IGF-1 Deficiency in a Cohort of Canadian Children with Short Stature Using a Novel Algorithm Tailored to Electronic Medical Records (2024, human observational)
Clinical characteristics and treatment efficacy in patients with primary severe IGF-1 deficiency treated with recombinant IGF-1 (2024, human observational)
Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency (2024, human case report)
Stigmasterol alleviates central precocious puberty by targeting the IGF-1/PI3K/Akt/mTOR signaling pathway and modulating the Kisspeptin/GnRH axis (2027, animal)
KNDy neurons as an indirect target of insulin-like growth factor-1 (2026, animal)
Recombinant human IGF-1 alleviates dyslipidemia induced by lactational maternal dietary restriction (2026, animal)
Alteration of IGF-1 bioavailability due to PAPPA2 deficiency leads to sex-specific metabolic disturbances (2025, animal)

Conditions researched

Related compounds

FAQ

What is IGF-1 LR3?

A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

How many registered human trials study IGF-1 LR3?

The PeptideWhiz trial index lists 47 registered trials for IGF-1 LR3, the most recent from 2026.

How much published research exists on IGF-1 LR3?

The PeptideWhiz paper index links 318 PubMed papers to IGF-1 LR3; by study type, 985 human and 380 animal studies.

Which conditions is IGF-1 LR3 researched for?

Muscle gain, sarcopenia & building muscle after 40, Acne, Anti-aging & longevity, Anxiety and panic, Atherosclerosis, cardiovascular disease & high blood pressure, Autism support, Chronic and systemic inflammation, Chronic pain: fibromyalgia & CRPS, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Dementia, Alzheimer's & cognitive decline, Eyes: macular degeneration & retinal health, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Female fertility, Fight-or-flight and nervous system overdrive, Gum disease (periodontal) & oral health, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, High-demand jobs: military, fire, police, EMT (and combat-sport athletes), Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Lung health, asthma & COPD, Lupus (SLE), Menopause & perimenopause, Multiple sclerosis, Muscle disease (myopathy), Osteoarthritis, cartilage loss & avoiding joint replacement, Osteoporosis and bone density, Parkinson's disease, PCOS, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Rheumatoid arthritis, Skin, hair loss, wounds & mast-cell/histamine reactivity, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides), Tendon, ligament, muscle & joint injuries (incl. athletes), Thyroid problems.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research